The proportion of patients observed to have received a reduced FXa-inhibiting DOAC dosage (11%-20%) is lower than previously published real-world DOAC use, for example, the ETNA-AF-EUROPE study reported 23.4% of patients receiving the reduced dose of edoxaban, whilst in the XANTUS study, 20.8% of patients receiving rivaroxaban were reported to have received the reduced dosage [24,33]. The gene discussed is F10; the disease is atrial fibrillation.